Compare FedEx Corporation (FDX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs ResMed Inc. — how do they compare? FedEx Corporation trades at $324.74 (market cap $76.28B), while ResMed Inc. trades at $224.8 (market cap $32.61B). The key difference: FedEx Corporation is far larger — about 2.3× ResMed Inc.'s market cap, and FedEx Corporation pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| FDX | RMD | |
|---|---|---|
Market Cap | $76.28B | $32.61B |
Sector | Industrials | Health |
52-Week High | $338.75 | $293.73 |
52-Week Low | $180.51 | $182.82 |
Enterprise Value | $105.91B | $31.97B |
Dividend Yield | 1.51% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $325.08, up 2.04% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $360.27 highlight positive momentum. The company's network transformation and focus on premium shipments are driving operational improvements, though revenue has been flat year-over-year. Cash flow trends show a projected rebound in 2026, with net cash flow turning positive.
The outlook for FDX is favorable, supported by cost-cutting initiatives and strategic shifts toward high-margin business. Key risks include competitive pressures and macroeconomic sensitivity. With 57% of analysts rating it a buy and institutional interest growing, the stock presents a compelling opportunity for growth-oriented investors, albeit with exposure to economic cycles.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
